Once the symbol of 1960s counterculture, psychedelic drugs have taken an unexpected and powerful detour into one of the most disciplined corners of modern society: the executive suite. In a recent feature by Emma Goldberg for The New York Times, she sheds light on how high-level executives—once the face of corporate rigidity—are turning to LSD, psilocybin, and other psychedelics to fuel creativity, reduce stress, and unlock new levels of emotional intelligence. This shift is not a passing trend. It reflects a deeper evolution in business culture, where leaders are increasingly seeking tools that connect them with their intuition, compassion, and creative essence. With guidance from therapists and specialized retreats, executives are incorporating microdosing and psychedelic journeys into their wellness routines—not to escape the demands of leadership, but to become better at it. Welcome to the era of psychedelic drugs in leadership! Psychedelic Drugs Enter the Executive Suite Psychedelic drugs—substances like LSD, psilocybin (found in magic mushrooms), MDMA, and ketamine—have been federally banned since the early 1970s. Despite their classification, usage is on the rise. According to a 2023 RAND Corporation report, approximately 8 million adults in the United States used psilocybin last year. While historically tied to underground or spiritual